Programs
Clinical Trials
Firmonertinib
ArriVent is studying firmonertinib (previously furmonertinib) globally in patients with NSCLC with EGFR exon 20 insertion mutations and EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations. To learn more about these clinical studies, please select from below or visit clinicaltrials.gov.
ARR-217
Study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Learn more at clinicaltrials.gov/study/NCT07066657
ARR-002
Study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.
Learn more at clinicaltrials.gov/study/NCT07755436
FURTHER (FURMO-002)
Study of Firmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR including PACC Mutations (NCT05364073)
Learn more at clinicaltrials.gov/study/NCT05364073
FURVENT (FURMO-004)
First-line Study to Compare Firmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (NCT05607550)
Learn more at clinicaltrials.gov/study/NCT05607550
ALPACCA (FURMO-006)
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator’s Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (NCT07185997)
Learn more at clinicaltrials.gov/study/NCT07185997
SHP2 Combination Trial
Study of Furmonertinib in combination with ICP-189, a SHP2 (SHP2i), in collaboration with Beijing InnoCare Pharma Tech Co., Ltd., in classical EGFRm Non-Small Cell Lung Cancer Patients
